不同表型中轴型脊柱关节炎的临床与影像学结局:DESIR队列5年分析
基于DESIR队列576例临床诊断中轴型脊柱关节炎患者,基线经潜在类别分析分为「纯中轴型」「中轴伴外周征象」「高危中轴型」三种表型,随访至5年。高危型患者残疾与生活质量随时间差于纯中轴型,BASFI平均高0.4分;影像学结局以纯中轴型更差。
要点
- 高危型中轴型脊柱关节炎患者5年内BASFI较纯中轴型平均高0.4分(β 0.4,95%CI 0.2至0.7)。
- 高危型与纯中轴型残疾差异在接受bDMARD者中更大(β=0.6 vs 0.5),纯中轴型BASFI改善更多(∆BASFI -1.3 vs -0.9)。
- 纯中轴型与中轴伴外周征象型在残疾和生活质量上无差异,影像学结局以纯中轴型更差。
核心结论
- 高危型中轴型脊柱关节炎患者随时间自报结局更差,且较经典中轴型表型更不可能从抗炎治疗中获益。
研究设计与样本
- DESIR队列中临床诊断中轴型脊柱关节炎患者,基线经潜在类别分析分为纯中轴型、中轴伴外周征象型和高危型三种表型,随访至5年。
- 共纳入576例中轴型脊柱关节炎患者,采用多变量GEE模型检验基线表型与各结局的关联。
主要发现
- 高危型患者随时间残疾(BASFI)和qol(SF36)差于纯中轴型患者,BASFI平均高0.4分(β 0.4,95%CI 0.2至0.7)。
- 该差异主要见于HLA-B27阳性的女性患者。
- 接受bDMARD者中高危型与纯中轴型差异更大(β=0.6 vs 0.5),纯中轴型BASFI改善更多(∆BASFI -1.3 vs -0.9)。
- 纯中轴型与中轴伴外周征象型在残疾和生活质量上无差异。
- 影像学结局随时间以纯中轴型更差。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare the long-term outcomes of three phenotypes of axial SpA (axSpA). METHODS: Patients with a clinical diagnosis of axSpA from the DESIR cohort were grouped into three phenotypes at baseline: 'Pure axSpA' ('Axial'), 'axSpA with peripheral signs' ('IBP+Peripheral') and 'axSpA at risk' ('At risk') by latent class analysis. Clinical and imaging data were collected up to 5 years. Clinical outcomes, measured in each visit, included disability (BASFI) and quality of life (QoL; SF36). Imaging outcomes included inflammatory and structural lesions on MRI and radiographs of spine and SIJ. The association between phenotype membership at baseline and each outcome was tested in multivariable GEE models. RESULTS: In total, 576 patients with axSpA were included. 'At risk' patients had worse disability and QoL than 'Axial' patients over time. For instance, 'At risk' patients had on average 0.4 more points in BASFI over time than 'Axial' patients [β (95 % CI): 0.4 (0.2; 0.7)]. This difference was mostly noted in female patients who were HLA-B27 positive. In addition, the difference between the 'At risk' and 'Axial' phenotypes was higher in patients receiving bDMARDs than in those not (β=0.6 vs 0.5), since BASFI improved more in 'Axial' (∆BASFI: -1.3) than in 'At risk' (∆BASFI: -0.9) treated patients. There were no differences in disability and QoL between 'Axial' and 'IBP+Peripheral' patients. Imaging outcomes were worse in the 'Axial' phenotype than in the others over time. CONCLUSION: Patients with 'axSpA at risk' show worse self-reported outcomes over time and are less likely to benefit from anti-inflammatory treatment than those with a classical axSpA phenotype.
引用
- Sepriano A, Ramiro S, van der Heijde D, et al. Clinical and imaging outcomes of different phenotypes of axial spondyloarthritis: 5-year analysis of the DESIR cohort. Semin Arthritis Rheum. 2024. PMID: 38479110. doi:10.1016/j.semarthrit.2024.152424
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。